NCT01203852
Pharmacogenomic Evaluation of Antihypertensive Responses 2
See it on ClinicalTrials.gov ↗839 people
51.1%
48.9%
429 womenmiddle line = equal numbers410 men
- Phase
- PHASE4
- Paid for by
- University of Florida
- Finished
- 2014-04
- Health conditions
- Hypertension
- Who could join
- Anyone
- Ages
- 18 Years – 65 Years
- Average age
- mean 50.3 years
- Age 65+
- 0%
- Weight (BMI)
- Not reported
- Pregnancy recorded
- Not reported
- Menopause recorded
- Not reported
- Results shown by sex
- Not split by sex
- Race
- Not reported
Women left out
- No pregnant women
Women who were pregnant could not join.
“Pregnancy or lactation”
- No breastfeeding moms
Women who were breastfeeding could not join.
“Pregnancy or lactation”
- No hormonal birth control
Women on the pill, patch, ring, shot, implant or hormonal IUD could not join.
“Current treatment with NSAIDS, cyclooxygenase-2 (COX2) inhibitors, oral contraceptives or estrogen.”
- No kidney or liver problems
Women with kidney or liver problems were turned away.
“Renal insufficiency (serum creatinine \> 1.5 in men or 1.4 in women)”
- No heart disease
Women with heart disease, heart rhythm problems or a past heart attack were turned away.
“Known cardiovascular disease (including history of angina pectoris, heart failure, presence of a cardiac pacemaker, history of myocardial infarction or revascularization procedure, or cerebrovascular disease, including stroke and TIA)”
- No diabetes
Women with diabetes were turned away.
“Diabetes mellitus (Type 1 or 2)”
Study titles and rules are shown in their original English.